NASH

Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened Conatus, which is developing emricasan along with Novartis AG (NYSE: NVS) for treating...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) — which is a frontrunner along with Gilead Sciences, Inc. (NASDAQ: GILD) in the non-alcoholic steatohepatitis drug development race — reported positive top-line results Tuesday for a late-stage study of its pipeline asset Ocaliva,...

With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the spotlight.  A clinical readout from the trial is expected this quarter. The...

Lipocine Inc (NASDAQ: LPCN) shares were skyrocketing Thursday following the release of results from a study evaluating LPCN 1144, its pipeline asset for non-alcoholic steatohepatitis, or NASH. What Happened Lipocine announced Thursday that eight-week top-line, interim results from an ongoing...

The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) jumped nearly 10 percent early Friday morning after the company provided an update on an ongoing clinical trial. Intercept is a biopharmaceutical company that focuses on developing and commercializing therapeutics to treat progressive non-viral...

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in a person's liver. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, there are no approved medicines to treat NAFLD and NASH. In a...

Allergan plc Ordinary Shares (NYSE: AGN)'s acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA) has some analysts wondering: if Allergan is willing to pay a massive 500 percent premium for Tobira, then what could possibly come next? Barrons cited Kevin Kedra, an analyst at Gabelli, who...

Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...

Shares of Tobira Therapeutics Inc (NASDAQ: TBRA) soared higher by more than 700 percent on Tuesday after the company was acquired by Allergan plc Ordinary Shares (NYSE: AGN). The massive premium Allergan is paying in Tobira's stock price has many investors questioning if any of Tobira's peers are...

Tobira Therapeutics Inc (NASDAQ: TBRA), a clinical-stage bio-pharmaceutical company that focuses on the development of therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, soared higher by more than 760 percent on Tuesday after the company agreed to sell itself to...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares have declined 63.88 percent over the past six months, reaching a low of $99.32 on January 28. Morgan Stanley’s Andrew S. Berens has upgraded the rating on the company from Underweight to Equal-Weight, with a price target of $100....